[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Savara Inc (SVRA)

Savara Inc (SVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,080,720
  • Shares Outstanding, K 205,460
  • Annual Sales, $ 0 K
  • Annual Income, $ -118,840 K
  • EBIT $ -144 M
  • EBITDA $ -146 M
  • 60-Month Beta 0.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.83

Options Overview Details

View History
  • Implied Volatility 104.59% (-21.09%)
  • Historical Volatility 47.14%
  • IV Percentile 6%
  • IV Rank 4.27%
  • IV High 1,135.35% on 03/19/26
  • IV Low 58.60% on 08/26/26
  • Expected Move (DTE 19) 0.55 (10.50%)
  • Put/Call Vol Ratio 13.35
  • Today's Volume 244
  • Volume Avg (30-Day) 536
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 5,444
  • Open Int (30-Day) 7,985
  • Expected Range 4.71 to 5.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 4
  • High Estimate $-0.15
  • Low Estimate $-0.16
  • Prior Year $-0.14
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.14 +2.33%
on 08/14/26
5.99 -12.19%
on 08/07/26
-0.07 (-1.31%)
since 07/28/26
3-Month
4.73 +11.21%
on 06/09/26
6.47 -18.76%
on 07/07/26
+0.17 (+3.34%)
since 05/28/26
52-Week
3.19 +64.68%
on 08/29/25
7.01 -24.91%
on 12/12/25
+1.99 (+60.86%)
since 08/28/25

Most Recent Stories

More News
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

-- Company to Host Industry Evening Mini-Symposium on aPAP with Renowned Key Opinion Leaders --

SVRA : 5.26 (-4.19%)
Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On August...

SVRA : 5.26 (-4.19%)
Will Savara's Quarter Reveal Whether Last Time's Miss Was Pattern or Exception?

Barchart Research What to Expect from SVRA Earnings SVRA Generated August 11, 2026 Current Price $5.57 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 5.06% Will Savara's Quarter Reveal Whether...

SVRA : 5.26 (-4.19%)
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026 MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in...

SVRA : 5.26 (-4.19%)
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARI’s Proprietary eFlow ® ...

SVRA : 5.26 (-4.19%)
Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June...

SVRA : 5.26 (-4.19%)
Savara Announces Chief Financial and Administrative Officer Transition

-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --

SVRA : 5.26 (-4.19%)
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 5.26 (-4.19%)
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking...

SVRA : 5.26 (-4.19%)
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 -- -- All Patients Receive Molgramostim During the OL Treatment Period;...

SVRA : 5.26 (-4.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States.

See More

Key Turning Points

3rd Resistance Point 5.69
2nd Resistance Point 5.60
1st Resistance Point 5.43
Last Price 5.26
1st Support Level 5.17
2nd Support Level 5.08
3rd Support Level 4.91

See More

52-Week High 7.01
Fibonacci 61.8% 5.55
Last Price 5.26
Fibonacci 50% 5.10
Fibonacci 38.2% 4.65
52-Week Low 3.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.